94 related articles for article (PubMed ID: 2133319)
1. [Leishmaniasis: effect of factors present in serum].
Savoia D; Cestaro A; Biglino S
G Batteriol Virol Immunol; 1990; 83(1-12):118-24. PubMed ID: 2133319
[TBL] [Abstract][Full Text] [Related]
2. Murine cutaneous leishmaniasis: resistance correlates with the capacity to generate interferon-gamma in response to Leishmania antigens in vitro.
Sadick MD; Locksley RM; Tubbs C; Raff HV
J Immunol; 1986 Jan; 136(2):655-61. PubMed ID: 3079789
[TBL] [Abstract][Full Text] [Related]
3. Antigen-stimulated lymphokines from patients with cutaneous leishmaniasis induce monocyte killing of Leishmania major intracellular amastigotes.
Passwell JH; Shor R; Trau H; Shoham J; Jaffe CL
J Immunol; 1987 Dec; 139(12):4208-12. PubMed ID: 3121732
[TBL] [Abstract][Full Text] [Related]
4. A trial of immunotherapy against Leishmania amazonensis infection in vitro and in vivo with Z-100, a polysaccharide obtained from Mycobacterium tuberculosis, alone or combined with meglumine antimoniate.
Barroso PA; Marco JD; Calvopina M; Kato H; Korenaga M; Hashiguchi Y
J Antimicrob Chemother; 2007 Jun; 59(6):1123-9. PubMed ID: 17439977
[TBL] [Abstract][Full Text] [Related]
5. Administration of monoclonal anti-IFN-gamma antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major.
Belosevic M; Finbloom DS; Van Der Meide PH; Slayter MV; Nacy CA
J Immunol; 1989 Jul; 143(1):266-74. PubMed ID: 2499629
[TBL] [Abstract][Full Text] [Related]
6. Reversible defect in antigen-induced lymphokine and gamma-interferon generation in cutaneous leishmaniasis.
Murray HW; Rubin BY; Carriero S; Acosta AM
J Immunol; 1984 Oct; 133(4):2250-4. PubMed ID: 6432909
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo effects of interleukin 2 on the protozoan parasite leishmania.
Mazingue C; Cottrez-Detoeuf F; Louis J; Kweider M; Auriault C; Capron A
Eur J Immunol; 1989 Mar; 19(3):487-91. PubMed ID: 2785043
[TBL] [Abstract][Full Text] [Related]
8. Resistance to macrophage-mediated killing as a factor influencing the pathogenesis of chronic cutaneous leishmaniasis.
Scott P; Sacks D; Sher A
J Immunol; 1983 Aug; 131(2):966-71. PubMed ID: 6863939
[TBL] [Abstract][Full Text] [Related]
9. The effector mechanism and vaccination against cutaneous leishmaniasis.
Liew FY
Behring Inst Mitt; 1991 Feb; (88):239-43. PubMed ID: 2049044
[TBL] [Abstract][Full Text] [Related]
10. Activation of the alternative complement pathway by Leishmania promastigotes: parasite lysis and attachment to macrophages.
Mosser DM; Edelson PJ
J Immunol; 1984 Mar; 132(3):1501-5. PubMed ID: 6363545
[TBL] [Abstract][Full Text] [Related]
11. Killing of Leishmania tropica amastigotes by factors in normal human serum.
Hoover DL; Berger M; Nacy CA; Hockmeyer WT; Meltzer MS
J Immunol; 1984 Feb; 132(2):893-7. PubMed ID: 6690622
[TBL] [Abstract][Full Text] [Related]
12. Regulation of activated macrophage antimicrobial activities. Cooperation of lymphokines for induction of resistance to infection.
Davis CE; Belosevic M; Meltzer MS; Nacy CA
J Immunol; 1988 Jul; 141(2):627-35. PubMed ID: 3133412
[TBL] [Abstract][Full Text] [Related]
13. Factors influencing the host response to Leishmania mexicana.
Pérez H
Ciba Found Symp; 1983; 99():157-73. PubMed ID: 6227462
[TBL] [Abstract][Full Text] [Related]
14. Cellular and humoral immunity to Leishmania major in genetically susceptible mice after in vivo depletion of L3T4+ T cells.
Sadick MD; Heinzel FP; Shigekane VM; Fisher WL; Locksley RM
J Immunol; 1987 Aug; 139(4):1303-9. PubMed ID: 3112230
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of vaccination with a combination of Leishmania amastigote antigens and the lipid A-analogue ONO-4007 for immunoprophylaxis and immunotherapy against Leishmania amazonensis infection in a murine model of New World cutaneous leishmaniasis.
Calvopina M; Barroso PA; Marco JD; Korenaga M; Cooper PJ; Nonaka S; Hashiguchi Y
Vaccine; 2006 Jul; 24(27-28):5645-52. PubMed ID: 16621179
[TBL] [Abstract][Full Text] [Related]
16. Chemokines in host-parasite interactions in leishmaniasis.
Teixeira MJ; Teixeira CR; Andrade BB; Barral-Netto M; Barral A
Trends Parasitol; 2006 Jan; 22(1):32-40. PubMed ID: 16310413
[TBL] [Abstract][Full Text] [Related]
17. [Immunopathogenesis of Leishmania infections].
Yurdakul P
Mikrobiyol Bul; 2005 Jul; 39(3):363-81. PubMed ID: 16358498
[TBL] [Abstract][Full Text] [Related]
18. Exacerbation of murine cutaneous leishmaniasis by adoptive transfer of parasite-specific helper T cell populations capable of mediating Leishmania major-specific delayed-type hypersensitivity.
Titus RG; Lima GC; Engers HD; Louis JA
J Immunol; 1984 Sep; 133(3):1594-600. PubMed ID: 6205088
[TBL] [Abstract][Full Text] [Related]
19. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice.
Tonui WK; Mbati PA; Anjili CO; Orago AS; Turco SJ; Githure JI; Koech DK
East Afr Med J; 2001 Feb; 78(2):90-2. PubMed ID: 11682953
[TBL] [Abstract][Full Text] [Related]
20. [Leishmaniasis: principles of the immune response and function of nitric oxide].
Bogdan C
Berl Munch Tierarztl Wochenschr; 1998; 111(11-12):409-14. PubMed ID: 9880934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
